相关实验视频

Updated: Jan 11, 2026

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

通过转录组学识别与静脉血栓塞栓症中的淋巴血管生成相关的关键基因,并通过RT-qPCR进行验证

Yusheng Lin^1,2, Jiahan Wu², Pucheng Wang²

¹Guangxi University of Chinese Medicine, Nanning, China.

Frontiers in medicine

|November 10, 2025

概括

这项研究确定MYC和NTAN1是静脉血栓塞栓症 (VTE) 的关键基因,将血栓与免疫和代谢变化联系起来. 这些发现为VTE治疗提供了新的治疗点.

科学领域:

心血管生物学心血管生物学
分子遗传学分子遗传学
免疫学免疫学免疫学

背景情况:

静脉血栓塞栓症 (VTE) 涉及到血栓和免疫失调之间的复杂相互作用.
淋巴细胞生成相关基因 (LRG) 可能通过影响内皮功能,凝血或炎症来影响VTE.

研究的目的:

为了确定与VTE相关的关键淋巴细胞生成相关基因 (LRGs).
阐明涉及VTE病变的分子机制和途径.
探索VTE的潜在治疗点.

主要方法:

对转录组数据集的分析,以识别VTE中的差异表达基因 (DEGs).
对DEG与LRG重叠的选,然后进行功能和通路分析.
机器学习,免疫透分析和网络建设的应用,用于通过RT-qPCR识别和验证关键基因.

主要成果:

确定了810个DEGs,MYC和NTAN1被优先考虑为关键基因.
MYC和NTAN1在结合体,氧化酸化和与免疫相关的途径中富含,与调节性T细胞和M2巨细胞相关.
一个监管网络将MYC确定为一个枢纽,潜在的药物目标包括西斯和奥拉帕里布.

结论:

MYC和NTAN1被确定为VTE的关键调节剂,将血栓性进展与免疫代谢失调联系起来.
这项研究为推动VTE的关键基因提供了新的见解.
这些发现表明,针对MYC和NTAN1.1,对VTE的潜在免疫调节疗法.

关键词:

免疫透免疫透是什么?关键的基因关键的基因与淋巴细胞生成相关的基因机器学习是机器学习.静脉血栓塞栓症是一种静脉血栓塞栓.

更多相关视频

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Published on: May 1, 2015

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...